Pharmacological Approaches in the Management of Depression: Current Therapies and Emerging Targets

Depression is a serious mental condition that causes poor energy, a loss of interest in daily tasks, persistent dissatisfaction, and trouble thinking clearly. It might affect how someone learns, works, and engages with others. It affects more than 300 million people worldwide and is currently one of the main causes of disability and a serious global health concern (1). The World Health Organization states that depression is a serious worldwide health problem that raises the risk of illness and suicide. Furthermore, they estimate that by 2030, it might be the second biggest cause of the total burden of illness (2).

Numerous interrelated biochemical changes can lead to depression. These include issues with monoamine neurotransmitters, an overactive HPA stress system, elevated inflammation, decreased brain plasticity, and disruptions in the gut-brain link (3,4). Modern antidepressants still have a number of disadvantages, although they primarily function by altering monoamine levels in the brain. Many individuals find only partial alleviation, a delayed rate of healing, or therapy resistance. Unwanted side effects are also experienced by some. These problems make it imperative to create new, more potent therapy choices (5).

Because they often have fewer negative effects and impact several body circuits, herbal and nutraceutical alternatives to traditional antidepressant drugs are becoming more and more popular. Some herbs that have shown great promise for reducing anxiety and depression include Withania somnifera (Ashwagandha), Passiflora incarnata (Passionflower), Crocus sativus (Saffron), and Hypericum perforatum (St. John's wort). By influencing brain neurotransmitters like GABA and monoamines, as well as by having anti-inflammatory and protective qualities, they enhance overall mental health (6–8).

Additionally, patients who don't get adequate relief from standard antidepressant medications now have hope thanks to novel treatments like NMDA receptor blockers, medications that increase neurotrophins, psychedelic-based therapies, and techniques that enhance gut flora (9,10). This study provides a comprehensive summary of current antidepressant medications, including herbal alternatives, and identifies novel therapeutic targets that may enhance the management of depression in the future.

Epidemiology and Burden of Depression

People of all ages, genders, and backgrounds are susceptible to depression, a prevalent mental health issue. Over 300 million people, or roughly 4–5% of the world's population, are affected globally. It continues to be one of the most prevalent psychological conditions, affecting day-to-day functioning, feelings, and general wellbeing (11). About 10–20% of persons will experience major depressive illness at least once in their lifetime. Additionally, studies reveal that women are almost twice as likely as males to experience depression (12). Gender differences in this illness are mostly due to differences in hormones, daily stress, and hereditary risk factors (13).

According to the World Health Organization, depression is a major contributor to years of life lost (YLLs) from suicide and self-harm as well as years lived with disability (YLDs) (14). Depression affects almost 50 million DALYs globally, resulting in a significant loss of healthy life years. Additionally, it significantly affects day-to-day functioning, resulting in increased healthcare expenses, job-related challenges, and decreased productivity. Over 700,000 individuals worldwide commit suicide each year, and depression is a major contributing factor in many of these deaths. This demonstrates how severe and even fatal the illness may be (15).

Although depression affects people globally, its effects are significantly greater in low- and middle-income nations. People find it more difficult to acquire the assistance they require in these areas since they frequently lack adequate mental health services and have a shortage of qualified specialists (16). Depression is made more difficult to treat by social stigma, limited access to mental health services, and frequent underdiagnosis; many people receive treatment after the fact, which can result in long-term issues; the COVID-19 pandemic increased this burden by causing lockdowns, financial strain, and a discernible rise in depressive symptoms (17,18).

Collectively, Depression as a whole has a significant negative social and economic impact on individuals all around the world. These results highlight the severity of the issue and highlight the need for improved therapies, early detection, and more robust mental health support networks.

2. Pathophysiology of Depression

Depression affects multiple bodily systems and is caused by a variety of interrelated variables. Changes in brain chemistry, hormones, the immune system, and even genetics are all part of its complicated scientific basis. In the past, researchers mostly concentrated on the monoamine theory, which postulated that depression symptoms were caused by low levels of neurotransmitters including dopamine, serotonin, and norepinephrine. However, we now understand that these substances are not the only factors that affect depression (19). Even though this hypothesis explains how the majority of conventional antidepressants function, it is still unable to adequately explain why depression varies so much among people or why these medications take weeks to start working (20).

2.1 Monoamine Dysregulation

Feeling depressed, losing interest in activities, and having difficulty thinking properly are all indications of low serotonin, norepinephrine, and dopamine levels in the synapse. Research indicates that individuals with depression frequently have reduced amounts of specific products of monoamine breakdown in their cerebrospinal fluid. This supports the theory that monoamines play a significant part in the disease, as does the fact that medications like reuptake blockers and MAOIs assist alleviate symptoms (22). While decreasing monoamine levels in healthy individuals does not consistently result in depression, this implies that other biological processes must also be crucial in the condition (20).

2.2 HPA Axis Dysfunction

The hypothalamic-pituitary-adrenal (HPA) axis may work harder than usual under prolonged stress. The body releases more cortisol and corticotropin-releasing hormone (CRH) when this system is hyperactive. The brain's natural feedback system, which is meant to maintain equilibrium, is weakened over time by the persistent increase in these stress chemicals. This may cause issues with mood regulation and shrinking of the hippocampus, an area crucial for memory and emotional regulation (23). Cortisol levels are frequently discovered to be greater than usual in depressed people, and their systems frequently react improperly to the dexamethasone suppression test. This indicates that the typical cortisol decrease that should follow dexamethasone use does not take place as anticipated (24).

2.3 Inflammation and Immune Dysregulation

An increasing body of evidence indicates that depression may be significantly influenced by inflammation. Increased levels of inflammatory markers, such as TNF-α, IL-6, and C-reactive protein, are thought to affect behavior and mood, which can result in emotional and psychological changes (25). The chemical balance of the brain can be upset by immune activity. Inflammation can alter the body's processing of monoamines, impede the development of new neurons, and raise oxidative stress. When combined, these alterations may lead to the onset of depression (26). Individuals with depression that is resistant to therapy frequently exhibit elevated levels of inflammation in their bodies. Research indicates that an increase in specific inflammatory markers may affect how the brain reacts to standard antidepressant therapies (27).

2.4 Neuroplasticity and Neurotrophins

Depression is closely associated with reduced brain-derived neurotrophic factor (BDNF) and issues with synaptic plasticity. Long-term stress lowers BDNF levels, which can harm or kill neurons in the prefrontal cortex and hippocampal regions. Antidepressant medications, on the other hand, stimulate improved synaptic connections and encourage the creation of new neurons by raising BDNF levels (28). Ketamine and other novel fast-acting antidepressants primarily alter glutamate transmission in the brain. Compared to conventional therapies, this promotes synaptic development and strengthening, resulting in faster mood benefits (25).

2.5 Gut–Brain Axis

Because gut bacteria interact with the body's immune system, hormones, and even nerves—particularly through the vagus nerve and the short-chain fatty acids they produce—changes in these bacteria can have an impact on our mood (29). An imbalance in the gut health can interfere with regular bodily processes. This imbalance can impact the molecules that regulate mood and cause inflammation throughout the body. As a result, digestive issues may play a role in the emergence of anxiety and sadness (30).

2.6 Genetic and Epigenetic Factors

According to research, families may be responsible for 40% of the risk of depression. The body's reaction to stress and serotonin levels are regulated by a number of genes (31). Histone modifications and DNA methylation are examples of epigenetic modifications that can turn genes on or off without changing the DNA itself. These mechanisms influence our reaction to stress and demonstrate how our environment and genes interact to influence behavior and health (32). Depression results from a number of bodily systems malfunctioning. Reduced brain plasticity, elevated inflammation, hormonal abnormalities, and decreased neurotransmitters are all contributing factors. Mood and thought are impacted when these processes are disrupted. Understanding these processes enables researchers to develop novel therapies that go beyond the typical monoamine-based medications (33).

3. Current Pharmacological Treatments:-

Pharmacological therapy is still the main treatment for mild to severe depression. Most drugs work by changing the levels of key brain chemicals, while some more modern drugs have an impact on the glutamate and hormone systems. The choice of treatment is influenced by the patient's past pharmaceutical response, probable side effects, other medical conditions, and the severity of the symptoms (34,35).

• 1. Selective Serotonin Reuptake Inhibitors (SSRIs)
• SSRIs are usually chosen as the first line of treatment for depression since they are generally safe and well-tolerated. They work by keeping serotonin from being reabsorbed, which causes the brain's serotonin levels to rise. Common examples are paroxetine, citalopram, escitalopram, sertraline, and fluoxetine.
• Side effects could include nausea, trouble sleeping, problems with sexual function, or in rare cases, serotonin syndrome.
• Although many patients benefit from SSRIs, about one-third of them do not achieve full remission (36).

3.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

By blocking the reuptake of both serotonin and norepinephrine, SNRIs can reduce the mental and physical symptoms of depression. Common drugs in this class include desvenlafaxine, duloxetine, and venlafaxine.

Possible side effects include elevated blood pressure, restlessness, and stomach problems (37).

3.3 Tricyclic Antidepressants (TCAs)

Tricyclic antidepressants, such as amitriptyline, imipramine, and nortriptyline, work by blocking the reabsorption of monoamines. However, they also affect histamine, muscarinic, and α-adrenergic receptors, which has several negative effects. Because they can cause significant anticholinergic symptoms, heart-related issues, and overdose hazards, they are frequently only used when first-line treatments are inadequate (38).

3.4 Monoamine Oxidase Inhibitors (MAOIs)

Tranylcypromine and phenelzine are examples of monoamine oxidase inhibitors that work by preventing the degradation of neurotransmitters like dopamine and serotonin. However, their use is limited since they may react severely with meals that contain tyramine and elevate blood pressure. Due to their many drug interactions, they must be used very carefully (39).

3.5 Atypical and Novel Antidepressants

Atypical antidepressants target different neurotransmitter sites:

For patients who are unable to tolerate SSRIs or SNRIs, these alternatives are beneficial.

• 6. Rapid-Acting and Novel Mechanisms
• It often takes two to six weeks for individuals to experience any significant improvement with traditional antidepressants. Because they alter the glutamate system and increase the creation of synapses in the brain, more recent rapid-acting therapies act considerably more quickly. Compared to prior medications, this helps elevate mood more rapidly (28).
• For depression that is resistant to treatment, esketamine is an NMDA receptor blocker. By increasing glutamate activity, which promotes stronger synaptic connections in the brain, it acts swiftly and helps alleviate symptoms (42).
• Brexanolone is a neurosteroid that is particularly licensed to treat postpartum depression. It acts on GABA-A receptors. It aids in restoring equilibrium to the body and brain by stabilizing the disturbed neuroendocrine pathways (43).
  7. Adjunctive / Augmentation Therapies

• Doctors frequently add additional medicines to enhance the response when patients do not entirely improve with standard antidepressants. This could involve adding lithium as a mood stabilizer or utilizing specific atypical antipsychotics like quetiapine or aripiprazole. Thyroid hormone (T3) is sometimes used in tiny doses to boost the effects of antidepressants. Combining psychotherapy with pharmacological treatment typically yields better overall outcomes (44).

3.8 Limitations of Current Therapies

Even with many treatments available, about 30–40% of people with depression still don’t fully recover, which makes treatment-resistant depression a serious concern. Slow treatment response, chances of relapse, side effects, and difficulty sticking to medication all add to the problem. Because of this, there is a strong need for new therapies and better alternatives (45).

4. Risk Factors for Depression

Depression develops due to many different factors. Biological changes, psychological stress, and social or cultural pressures can all play a role. Together, these influences increase a person’s chances of experiencing the disorder.

4.1 Biological Factors

• Genetic influence: Research shows that depression can run in families. If someone has a first-degree relative—like a parent or sibling—living with depression, their own chances of developing it become two to three times higher than average.
• Chemical imbalance in the brain: Depression is also linked to disturbances in important brain chemicals. When neurotransmitters such as serotonin, dopamine, norepinephrine, GABA, or glutamate are not properly regulated, it can affect mood, motivation, and emotional stability.
• Hormonal and stress-related changes: The body’s stress-response system, especially the HPA axis, often becomes overactive in people with depression. This leads to consistently high cortisol levels, which can negatively impact mood and overall mental health.
• Role of inflammation: Studies have found that people with depression often show higher levels of inflammatory markers like IL-6 and TNF-α. These inflammatory responses may interfere with brain function and contribute to depressive symptoms (46).

4.2 Psychological Factors

• Personality traits: Individuals who often feel anxious, emotionally sensitive, or have low confidence tend to be more vulnerable to developing depression. Difficulty in handling stress also increases this risk.
• Childhood experiences: Facing hardships early in life—such as trauma, neglect, abuse, or losing a parent—can leave long-term emotional effects, making a person more prone to depression later on.

Thinking patterns: People who usually focus on the negative side of situations, feel powerless, or blame themselves in a pessimistic way are more likely to experience depressive episodes or relapse (47).

• 3. Sociocultural and Environmental Factors
• Chronic stress: Prolonged stress from job, school, or financial difficulties can build up over time and result in depressed symptoms.
• Limited social support: People who don't have close friends or family to turn to or who feel lonely are more prone to depression.
• Substance abuse: Regular drug, alcohol, or cigarette use can disrupt emotional balance and worsen symptoms of depression.
• Significant life changes: Losing a loved one, going through a divorce or split, having a chronic illness, or losing a career are all strong emotional stressors that can lead to depression (48).

5. Emerging Novel Therapies and Molecular Targets

Recent developments in neurobiology have opened up new therapeutic options for depression, especially for those who do not respond well to traditional therapies. Instead of relying only on traditional monoamine-based drugs, researchers are now looking into treatments that target deeper biochemical circuits. These innovative approaches aim to improve neuroplasticity, reduce inflammation, regulate glutamate activity, and balance neuroendocrine systems. By concentrating on these pathways, new therapies may be able to assist patients with treatment-resistant depression more rapidly and effectively (28).

5.1 Psychedelic-Based Therapies

• Psychedelic substances have been the subject of much recent research due to their unique effects on the brain's serotonin system.
• The potential therapeutic effects of substances including psilocybin, LSD, and DMT are being investigated.
• These substances primarily activate 5-HT2A receptors, which may aid in the development of new neural connections and promote emotional recovery.
• Preliminary research indicates that some patients exhibit discernible improvement even after just one or two treatment sessions when these medications are used in conjunction with guided psychotherapy (49).       

5.2 Anti-inflammatory & Immunomodulatory Agents

• Studies reveal that inflammation contributes significantly to the onset of depression, and lowering it may enhance mood.
• Because they may reduce inflammatory signals associated with depression symptoms, cytokine-blocking medications, such as those that target TNF-α or IL-1, are being researched.
• The ability of certain NSAIDs and COX-2 inhibitors to lessen depressive symptoms by lowering inflammation is currently being investigated.
• In addition to being an antibiotic, minocycline has potent anti-inflammatory and protective effects on brain cells, and recent research indicates that it may aid in the recovery of some forms of depression (50).

5.3 Neurotrophic & Neurogenesis Enhancers

• Agents that boost BDNF levels or directly activate TrkB receptors help strengthen synaptic connections, which supports better brain communication and mood regulation.
• Compounds like IGF-1 and Erythropoietin have shown promising results in studies, as they seem to enhance neuroplasticity and support the brain’s ability to recover and adapt (51).
  4.  Hormonal & Neuroendocrine Therapies

• Brexanolone is a synthetic version of allopregnanolone, a naturally occurring hormone. It is the first medication designed especially to treat postpartum depression that has received FDA approval. It promotes quick mood improvement and aids in reestablishing the hormonal balance that is upset during childbirth (43).
• Zuranolone (SAGE-217) is an oral neurosteroid that works in a similar way, but it is taken by mouth instead of through infusion. It is still being studied, and early research shows that it may offer a short-course, effective treatment option for different types of depression (52).
  5. Gut Microbiome–Based Interventions

• Probiotics, sometimes referred to as "psychobiotics," are beneficial microorganisms that support mental wellness. By supporting gut health, they may reduce symptoms of depression and stress.
• Prebiotics and Dietary Polyphenols: Foods rich in prebiotics and natural plant components encourage the growth of healthy gut flora. This maintains the equilibrium of the intestinal environment, which could improve mood.

• Fecal Microbiota Transplantation (FMT): This technique transfers a donor's healthy gut flora. FMT seeks to address serious microbiome imbalances that may be connected to mental health problems, however research is still ongoing.
• Overall Effect on the Body: These therapies affect the brain through the gut-brain axis by improving the gut flora (53,54).

5.6 Stem Cell & Gene-Based Approaches

• Mesenchymal stem cell therapy: Being explored as a new treatment option because they can reduce inflammation and release helpful growth factors (55).
• CRISPR/Cas-based modulation: CRISPR/Cas technology is opening new possibilities for treating psychiatric disorders by directly targeting the genes involved in mood, behaviour, and brain function (56).
  6. Digital & Neuromodulation therapies
• Transcranial Magnetic Stimulation (TMS): Corrects aberrant neural activity by applying magnetic pulses to particular brain regions to elevate mood.
• Transcranial Direct Current Stimulation (tDCS): This technique softly stimulates brain cells and promotes improved emotional regulation by applying a very low electrical current to the scalp.
• Vagus Nerve Stimulation (VNS): This technique involves stimulating the vagus nerve to affect brain areas related to stress management and mood.
• Deep Brain Stimulation (DBS): This more intrusive technique, which places electrodes in deeper brain regions to correct malfunctioning circuits, is only utilized in really severe, treatment-resistant situations (57).
  7. Herbal drugs: